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Real time polymerase chain reaction (PCR)Bovine venereal campylobacter infection, caused by Campylobacter fetus venerealis, is of signiﬁcant economic
importance to the livestock industry. Unfortunately, the successful detection and discrimination of C. fetus
venerealis from C. fetus fetus continue to be a limitation throughout the world. There are several publications
warning of the problem with biotyping methods as well as with recent molecular based assays. In this study,
assessed on 1071 isolates, we report on the successful development of two Real Time SYBR® Green PCR
assays that will allow for the detection and discrimination of C. fetus fetus and C. fetus venerealis. The sensitivity
reported here for the C. fetus (CampF4/R4) and the C. fetus venerealis (CampF7/R7) speciﬁc PCR assays are 100%
and 98.7% respectively. The speciﬁcity for these same PCR assays are 99.6% and 99.8% respectively.
Crown Copyright © 2013 Published by Elsevier B.V. Open access under CC BY license.1. Introduction
The species Campylobacter fetus is divided into the subspecies
C. fetus subsp. venerealis (Cfv) and C. fetus subsp. fetus (Cff). It has
been documented that Cfv, unlike Cff, cannot survive in the bovine
intestine (Caldow and Taylor, 1997; Skirrow, 1994). However, it is
highly adapted to the genital tract of cattle and is recognised as the
causative agent of bovine venereal campylobacteriosis (BVC), which
can lead to serious reproductive problems such as infertility and abor-
tion. Cff can be isolated from the gastrointestinal tract of a wide range
of host species and is only sporadically associated with abortions
in both sheep and cattle. In contrast with Cfv, Cff can be recovered
from the genital tracts with no associated clinical symptoms. Both
organisms differ in their epidemiology and clinical importance, with
BVC being classed as a statutory disease in the UK, and thus controlled
by legislation. Consequently, in accordance with theWorld Organisation
for Animal Health (OIE), all bulls in the UK are screened for Cfv if they are
to be used for international trade purposes.
Since Cfv is the causative agent of BVC with major economical
concerns for the cattle industry, the accurate differentiation from Cff
is essential. Differential diagnosis between Cfv and Cff is notoriously dif-
ﬁcult, whether it be bymicrobiological/biochemical typing (biotyping),ross, Nr. Exeter, Devon, EX6 8PE,
k (A. McGoldrick).
ier B.V. Open access under CC BY licenELISA, DIFT or molecular based assays (PCR, AFLP and PFGE). The differ-
entiation of C. fetus subspecies by traditional biotyping methods is
primarily based on a small number of reactions (On, 1996), namely,
antibiotic sensitivity (metronidazole and cefoperazone or nalidixic
acid and cephalothin), growth at 25 °C and 42 °C, susceptibility to
basic fuchsin and KMnO4, sodium selenite reduction, production of hy-
drogen sulphide through the utilisation of cysteine and tolerance to 1%
glycine. The latter test tends to be most commonly used by diagnostic
laboratories worldwide since it is OIE approved and unlike Cff, Cfv can-
not tolerate 1% glycine (Anon, 2012). However, data accumulated to
date, including this report, would tend to indicate that the use of very
few discriminatory tests for the phenotypic characterisation of C. fetus
species may lead to misidentiﬁcation and erroneous classiﬁcation of
subspecies (Vargas et al., 2003). This is particularly important when
looking at tolerance to glycine, which although used as a differential
diagnosis for subspecies of C. fetus, is not a reliable indicator (Abril
et al., 2007; Chang and Ogg, 1971; Vargas et al., 2003; Willoughby
et al., 2005). It is worth noting that an additional group of Cfv isolates,
termed C. fetus venerealis biovar “intermedius” (Cfvi), can tolerate higher
concentrations (N1%) of glycine (Salama et al., 1992). Problematic dis-
crimination based on other biotyping tests has also been demonstrated
with respect to H2S production (Vargas et al., 2003) and antibiotic sensi-
tivity (Schulze et al., 2006). Therefore, the potential misidentiﬁcation of
Cff from genital tracts based on biotyping methods may warrant further
investigation. An additional complication in the detection and identiﬁca-
tion methods for Cfv was also evident when testing varied dramatically
from laboratory to laboratory (van Bergen et al., 2005a). Such large
variation between laboratories may also increase the potential risk
of misidentiﬁcation/classiﬁcation.se.
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alternative discriminatory methods based on molecular techniques,
predominantly using polymerase chain reaction (PCR) or ampliﬁed
fragment length polymorphism — AFLP (van Bergen et al., 2005b;
Wagenaar et al., 2001). As a direct consequence, several papers have
been published to try to detect and discriminate between Cfv and Cff
(Abril et al., 2007; Chaban et al., 2012; Harwood et al., 2009; Hum
et al., 1997; Iraola et al., 2012; Moolhuijzen et al., 2009; Muller et al.,
2003; Oyarzabal et al., 1997; Schulze, et al., 2006; Spence et al., 2011;
Vargas et al., 2003; Willoughby, et al., 2005). Unfortunately, these
PCR methods have either been questioned with regards to sensitivity
and/or speciﬁcity, or have usedmore labour intensive and less sensitive
gel-based assays with the ﬁrst probe based assay only reported in
March 2006 (McMillen et al., 2006). In 2007, Abril et al. reported
the presence of a unique insertion sequence (ISCef1) that may be a
potential target site to differentiate Cfv from Cff. More recently,
Moolhuijzen et al. (2009) highlighted the complexity of targeting
speciﬁc genes to allow the detection and differentiation of Cff and Cfv.
The aim of this study was to assess the feasibility of using PCR
targeted at published sequences to detect and discriminate between
Cfv and Cff isolates selected by biotyping methods. Preliminary studies
focused on the suitability of published PCR methods as well as the
potential development of ‘in-house’ Real Time SYBR® Green assays.
Once designed and the PCRs optimised, the second phase of the study
was to screen 1071 isolates representing both archived and NCTC
strains, as well as recent clinical isolates.
2. Materials and methods
In the ﬁrst phase of the study 15 biotyped isolates were chosen to
assess published as well as in-house PCR assays (Tables 1 & 2). Eleven
of these isolates were clinical samples derived from the Animal
Health and Veterinary Laboratories Agency (AHVLA) archive based
at Weybridge. They were isolated from clinical samples from both
ovine and bovine species collected from 2002 to 2008 (C1–C12).
The remaining four isolates comprised NCTC strains, representing
Campylobacter jejuni (NCTC 11351), Campylobacter coli (NCTC 12143),
C. fetus fetus (NCTC 10842), and C. fetus venerealis (NCTC 10354).
In the second phase of the study, 1071 bacterial isolates were
obtained from 3 sources. Three hundred and sixty three isolates
biotyped as being non C. fetus species were supplied by AHVLA labora-
tories based at Starcross, Winchester and Weybridge. These consisted of
45 Arcobacter sp. (including 3 NCTC strains 12713, 12481, 11885), 68
C. coli (including 1 NCTC strain 12413), 30 Campylobacter hyointestinalis,
132 C. jejuni (including 1 NCTC strain 11351), 7 Campylobacter lari
(including 1 NCTC strain 11352), 7 Campylobacter mucosalis, 67
Campylobacter sputorum, 1 Campylobacter upsaliensis, 1 HelicobacterTable 1
Details of the 9 PCR assays assessed in the initial phase of the study.
No Source Sub-species Original primers Renamed primers Sequ
1 Hum et al. (1997)a Cff & Cfv MG3F MG4R CampF1 CampR1 XXT
2 R Jonesb Cff & Cfv PanC-F PanC-R CampF2 CampR2 GCT
3 McGoldrick (In-house) Cff & Cfv CampF3 CampR3 TTTG
4 McGoldrick (In-house) Cff & Cfv CampF4 CampR4 GCG
5 Hum et al. (1997)a Cfv VenSF VenRF CampF5 CampR5 XXX
6 McMillen et al. (2006) Cfv CfvF CfvR CampF6 CampR6 XXC
7 McGoldrick (In-house) Cfv CampF7 CampR7 AAA
8 Abril et al. (2007) Cfv IVB376-L IVB376-R CampF8 CampR8 TAG
9 Abril et al. (2007) Cfv CVEN-L CVEN-R2 CampF9 CampR9 ATT
Cff — Campylobacter fetus fetus.
Cfv — Campylobacter fetus venerealis.
a Also used by Vagras et al. (2003), Muller et al. (2003), Schulze et al. (2006), McMillen
b Unpublished — based on Casademont et al. (1998).
c Modiﬁcations as shown. X's represent deletions.sp. and 5 NCTC isolates representing Escherichia coli (NCTC strain
10418), Proteus vulgaris (NCTC strain 4175), Salmonella nottingham
(NCTC strain 7832), Staphylococcus aureus (NCTC strain 6571), and
Streptococcus uberis (NCTC strain 3858). A further 485 biotyped
Cff and 223 Cfv isolates were obtained from AHVLA Weybridge and
AHVLA Winchester from both archived and recent bovine/ovine clinical
samples. Within the 1071 isolates, one NCTC strain of Cff (NCTC 10842)
and one Cfv (NCTC 10354) were also included.
Micro-aerobic isolates obtained fromAHVLA Starcrosswere grown on
5% sheep blood agar plates (Oxoid, Basingstoke, UK) in a CampyGen™
micro-aerobic jar (Oxoid, Basingstoke, UK) and incubated at 37 ± 2 °C
for 48 h. All other control bacterial isolates obtained from Starcross
were grown on sheep blood agar plates and incubated at 37 ± 2 °C
for 24 h. Samples provided by AHVLA Winchester were grown on 7%
sheep blood agar + 0.1% actidione plates (BACT) in a micro-aerobic in-
cubator at 37 ± 2 °C for 48 h. Finally, all isolates obtained from AHVLA
Weybridge were grown from frozen bead stocks (−80 °C) stored in
glycerol broth. Cultures were plated onto both Skirrows agar and 5%
sheep blood agar. Incubation was between 2 and 3 days at 37 ± 2 °C,
in a micro-aerobic atmosphere. All agar plates were supplied by the
media department based at Weybridge and prepared in accordance
with standard operating procedures (SOPs).
2.1. Biotyping
All samples were biotyped in accordance with United Kingdom
Accreditation Service (UKAS) accredited SOP BAC0089which is available
upon request. In brief, Campylobacter samples were biotyped using a
combination of oxidase, catalase, hippurate hydrolysis, indoxyl acetate,
T.S.I. agar, FBP broth, urease, cysteine and glycine. Growth checks were
undertaken under micro-aerobic conditions at 25 °C and 41.5 °C and
aerobically at 30 °C. Sensitivity patterns to Naladixic acid and Cephalo-
thin were also recorded. It was noted during the early stages of the
project that biotyping could be signiﬁcantly improved if the glycine
and cysteine sensitivity assays were performed using blood agar plates
instead of Mueller Hinton broths (containing 0.1% agar) as supplied by
AHVLA media department.
2.2. DNA extraction for PCR
DNAwas extracted from the bacterial cultures using a simple boiling
method. Single bacterial colonies were removed from each agar plate
using a 1 μl-inoculating loop and re-suspended in a ratio of 1 colony
to ~500 μl of sterile molecular biology grade water in a 1.5 ml screw-
cap microcentrifuge tube. The bacterial suspensions were vortexed for
10 s and brieﬂy centrifuged to remove any liquid from the lid prior
to being heated at 100 ± 2 °C for 10 min. Once cooled the bacterialencec Gene Size
AGCCGCAGCTGCTAAGAT TAGCTACAATAACGACAACTAT Carbon
starvation
protein
~750
AAGGGTGAGGTTGATGGG AAGTTATTCTTCAAATCTACC Sap B ~230
GTCGATGTTATGGTGA CGCGGTTAAAATTTGAGAAG nahE ~190
AGTTCGCTTTAGCTAT GGCTAAATGTCCGATGTTTTT nahE ~140
XXCAGTTTGCGATATTGCCATT XXTTTTGAGATAACAATAAGAGCTT Plasmid ~140
AGTTATCCCAAGCGATCT XXTTGGATTATAAATTTTAGCTTGGT Plasmid ~90
TGATAATTTAAAAACCATAGC TTCATTCCACTACCTAAGTCT ISCfe-1 ~150
CTTATGCAAGAGTTAGTTC CAGCTCCAAATCTTAATAATCT ISCfe-1 ~230
AGTATTTGCAATATGTGAAG AATTGATATTAAATTTGATTGATTAG ISCfe-1 ~230
et al. (2006), and Abril et al. (2007).
Table 2
Preliminary results of the 9 PCR assays using 15 isolates of Campylobacter.
ID AHVLA/NCTC
Ref No.
Host Species Biotype I.D. Hum
et al.
Casademont
et al.
McGoldrick
In-house
McGoldrick
In-house
Hum
et al.
McMillen
et al.
McGoldrick
In-house
Abril
et al.
Abril
et al.
CSP Sap B nahE nahE Plasmid Plasmid ISCe-1 ISCe-1 ISCe-1
Camp F1
Camp R1
PanC-F
PanC-R
Camp F3
Camp R3
Camp F4
Camp R4
Camp F5
Camp R5
Camp F6
Camp R6
Camp F7
Camp R7
Camp F8
Camp R8
Camp F9
Camp R9
Agarose SYBR®
Green
SYBR®
Green
SYBR®
Green
SYBR®
Green
SYBR®
Green
SYBR®
Green
SYBR®
Green
SYBR®
Green
Cff & Cfv Cff & Cfv Cff & Cfv Cff & Cfv Cfv Cfv Cfv Cfv Cfv
C1 BT04/210 Ovine Cff + + (27) + (15) + (15) − − − − −
C2 BT07/205 Ovine Cff + + (20) + (14) + (14) − − − − −
C4 BT07/210 Ovine Cff + + (25) + (14) + (14) − − − − −
C5 BT07/211 Ovine Cff + + (20) + (14) + (13) − − − − −
C6 BT05/148 Bovine Cfv + + (26) + (16) + (15) − − + (13) + (16) + (22)
C7 BT02/212 Bovine Cff + + (24) + (13) + (13) − − − − −
C8 BT03/040 Bovine Cfv + + (24) + (15) + (15) − − + (13) + (15) + (21)
C9 BT03/173 Bovine Cfvi + + (25) + (16) + (16) − − + (14) + (17) + (23)
C10 BT03/174 Bovine Cfvi + + (25) + (14) + (14) − − + (13) + (15) + (18)
C11 BT03/317 Bovine Cff + + (25) + (15) + (14) − − − − −
C12 BT03/318 Bovine Cff + + (22) + (14) + (13) − − − − −
C15 NCTC 11351 Unknown C. jejuni − − − − − − − − −
C16 NCTC 12143 Human C. coli − − − − − − − − −
C18 NCTC 10842 Sheep C. fetus fetus + + (22) + (15) + (15) − − − − −
C19 NCTC 10354 Bovine C. fetus venerealis + + (26) + (14) + (14) + (17) + (15) + (12) + (14) + (17)
Numbers in parentheses indicate Ct values, Cff — Campylobacter fetus fetus, Cfv — Campylobacter fetus venerealis, Cfvi — Campylobacter fetus venerealis intermedius.
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and stored at 4 °C until required for testing.
2.3. DNA analysis for PCR
Sequences pertaining to Cff and Cfv were downloaded directly
from the Genbank nucleotide database. The alignment and comparison
of DNA sequences were then undertaken with DNASTAR (Lasergene)
using EditSeq and MegAlign. The target DNA and accession numbers
(in parenthesis) were ISCfe-1 (AM260752, AM286430, AM286431),
Plasmid (EU443150, AY903214, AY750964), Carbon starvation protein
(AY158814), and nahE (AM286430, AM28643).
2.4. Published primers for PCR
As part of the preliminary phase of the study 9 PCR methodologies
were assessed, comprising 6 modiﬁed published and 3 in-house PCR
methods on a selection of 15 isolates (Table 1). In order to simplify
and standardise the methods, the published primers were modiﬁed
to align their annealing temperatures to approximately 58 °C and
renamed to have a ‘Camp’ preﬁx. All real time PCRswere then subjected
to the same cycling conditions as described in Section 2.7.
From Table 1, PCR assays 1 to 4 detected both Cff and Cfv, targeting
three different genes. Cfv speciﬁc PCR assays targeting either the plasmid
or ISCfe-1 sequence, namely PCR assays 5 to 9, were a mixture of
published and in-house designed assays.
2.5. Primer design for PCR
The unique insertion (ISCfe-1) and nahE sequences as published
by Abril et al. (2007) were used to design primers to allow real time
PCR ampliﬁcation. Primers were designed through the editing of the
target sequences in EditSeq and then using Primer3 Software v. 0.4.0
(Rozen and Skaletsky, 2000). Primers were further screened using an
NCBI Blast search to highlight any possible cross-reactions with other
published sequences (data not shown).
All primers were purchased commercially (Sigma Aldrich Company
Ltd, Gillingham, UK). All of the methods with the exception of
Hum et al. (1997) (CampF1/R1) were used with SYBR® Green asdescribed in Section 2.7, whilst CampF1/R1 PCR products were run
on a 1.5% agarose gel.2.6. Agarose gel PCR protocol
From Table 1, method 1 PCR mastermix consisted of 25 μl of Taq
PCR Master Mix (Qiagen Ltd, Crawlley, UK); 1 μl of each CampF1/R1
primer (20 pmol/μl) and 20.5 μl of molecular grade water (Qiagen Ltd,
UK). Into 96 well skirted PCR plates (Alpha Laboratories, Eastleigh,
UK), 47.50 μl of PCR mastermix was dispensed. To each well either,
2.5 μl of boilate, 2.5 μl of positive control material or 2.5 μl of water
acting as a no-template control was added prior to applying 8 cap strips
(Alpha Laboratories, Eastleigh, UK). The PCR cycle began with 3 min
at 95 °C, followed by 45 cycles of 95 °C for 30 s, 58 °C for 30 s and
72 °C for 1 min and concluded with 10 min at 72 °C. PCRs were car-
ried out using a Stratagene MX3000 and product detected by gel
electrophoresis.2.7. SYBR® green PCR protocol
From Table 1, methods 2–9 used a SYBR® Green PCR Master Mix
consisting of 12.5 μl of QuantiTect® SYBR Green PCR Master Mix
(Qiagen Ltd, Crawley, UK); 1 μl of each of the forward and reverse
primers (20 pmol/μl); and 8 μl of molecular biology grade water
(Qiagen Ltd, Crawley, UK). From the mastermix, 22.5 μl was dis-
pensed into each well of a Thermo-fast® 96 well, non-skirted, PCR
plate (ThermoScientiﬁc, Hemel Hempstead, UK). To each well either
2.5 μl of boilate, 2.5 μl of positive control material or 2.5 μl of water
acting as a no-template control was added, prior to applying ultra
clear cap strips (ThermoScientiﬁc, Hemel Hempstead, UK). The plates
were then placed in a StratageneMX3000 and subjected to the following
cycle conditions: 15 min at 95 °C, followed by 45 cycles of 95 °C for 30 s
and 58 °C for 1 min. Fluorescence data was collected at the 58 °C phase
using MxPro Software, version 4.0 (Stratagene, La Jolla, CA. USA). SYBR®
Green real-time PCR ampliﬁcation plots and dissociation curves were
viewed and analysed. Cycle Threshold (Ct) values and melting tempera-
tures for each positive sample were recorded.
Table 3
Summary of results — 1071 samples.
PCR Biotyping
Neg Cff Cfv
Neg 360 0 2
Cff 3 430 10
Cfv 0 55 211
Totals 363 485 223
202 A. McGoldrick et al. / Journal of Microbiological Methods 94 (2013) 199–2042.8. Ampliﬁed fragment length polymorphism (AFLP)
Thirty one isolates used in this studywere selected for testing at The
Central Veterinary Institute (Wageningen, Lelystad, The Netherlands)
for Campylobacter subspecies differentiation using ampliﬁed fragment
length polymorphism (AFLP) PCR.
2.9. Data analysis/statistics
The full data set of 1071 samples was assessed using Cohen's
Kappa to measure agreement. A McNemar test was also performed
on the pattern of differences between the biotyping and PCR methods.
This was undertaken across the 706 samples positive for Cf by both
methods in order to assess the null hypothesis that the two methods
were equally likely to identify samples as Cff or Cfv.
3. Results
From Tables 1 and 2, four C. fetus PCRs were compared; 3 real time
and 1 agarose gel based assay. Using the agarose gel-based assay of
Hum et al. (1997), with primer modiﬁcation and changes to cycling
conditions, of the 15 isolates tested, all of the 13 putative C. fetus isolates
gave an amplicon of ~750bp (data not shown). The 2 control strains C15
(C. jejuni) and C16 (C. coli) were not detected using these primer and
ampliﬁcation conditions.
Similarly the same 13 isolates were detected by all 3 Cfv/Cff Real
Time SYBR® Green assays using the CampF2/R2 primers based on
published sequences (Casademont et al., 1998) and in-house primers
CampF3/R3 and CampF4/R4. From Table 2, the CampF3/R3 and
CampF4/R4 real time assays, based on Ct values, were at least 2 to 3
logs more sensitive than the primers based on Casademont et al., when
used in combination with SYBR® Green. Based on the results and size of
amplicon, primers CampF4/R4 were chosen to test 1071 isolates in the
2nd phase of the study.
The two Cfv speciﬁc PCRs targeting the plasmid sequences, namely
CampF5/R5 based on Hum et al. (1997) and CampF6/R6 based on
McMillen et al. (2006), failed to detect Cfv samples C6, C8, C9 and
C10 but did detect the NCTC isolate C19 (Table 2). However, 3 other
Cfv speciﬁc PCRs based on the sequences and primers published by
Abril et al. (2007) correctly identiﬁed Cfv samples and did not cross
react with Cff or non C. fetus isolates (Table 2). Based on these results
and taking into consideration the size of amplicons, in-house primers
CampF7/R7 were taken forward to be assessed on the 1071 isolates.
All 1071 isolates were then tested with primer combinations
CampF4/R4 (C. fetus) and CampF7/R7 (Cfv speciﬁc), with all clinical
samples having been biotyped in accordance with UKAS accredited
method as described in Section 2.1. Isolates were denoted as being
Cfv if the PCR reactions using primers Camp F4/R4 and Camp F7/R7
were positive. If the sample was positive for primers Camp F4/R4, but
negative for primers Camp F7/R7, then the isolates were denoted as
Cff. It was not possible to have an isolate positive for only primers
Camp F7/R7 yet negative for primers Camp F4/R4, and this combination
was never found in the study.
From Table 3, 363 control isolates were chosen as described
in Section 2. Of the 363 isolates, 360 were not detected by either
the Cfv speciﬁc primers (CampF7/R7) or the C. fetus PCR primers
(CampF4/R4). Furthermore, all water (‘no-template’) controls set
up as part of each PCR run were shown to be negative (data not
shown) indicating that cross contaminationwas not an issue. Three iso-
lates were shown to be negative for C. fetus by biotyping yet gave posi-
tive results for Cff when tested by PCR. All 3 isolates were re-cultured
and 2 were subsequently biotyped as Cff with 1 isolate identiﬁed as
C. jejuni. Upon further investigation by PCR, the original boilate
remained positive for Cff whilst the boilate from the re-cultured isolate
was negative by PCR (data not shown).When biotyped, 223 samples were shown to be Cfv isolates. From
Table 3, two isolates were biotyped as Cfv, yet negative by PCR. Upon
re-culture both isolates were shown to be an Arcobacter sp. and had
beenmis-identiﬁed by biotypingmethods. Of the remaining 221 sam-
ples, 211 (96%) were conﬁrmed as Cfv by PCR with 25 also conﬁrmed
as Cfv by AFLP analysis (data not shown). One sample which was
positive for Cfv by both culture and PCR was shown to be negative
by AFLP (data not shown). There were further 10 samples that were
biotyped as Cfv but were shown to be indicative of Cff by PCR. Of
the 10 discrepancies, all were re-cultured, with 3 samples being further
analysed by AFLP. All 10 isolates were subsequently shown to be Cff by
re-culture and/or ALFP.
Further 485 samples were biotyped as Cff (Table 3). PCR analysis
showed all 485 isolates to be C. fetus, but only 430 (89%)were indicative
of Cff. Of the remaining 55 samples (11%) indicating the presence of Cfv
by PCR, 20were reculturedwith 1 of the 20 samples being sent for AFLP
analysis. Nineteen of the isolates were subsequently shown to be Cfv
when re-biotyped and not Cff as originally identiﬁed. However, one
isolate was re-biotyped and still shown to be Cff. The original boilate
was retested and remained positive for Cfv whilst the boilate of the
re-biotyped isolate indicated the presence of Cff by PCR.
Overall, the PCRs detected additional 55 Cfv isolates, additional 10
Cff isolates, questioned 2 Cfv culture identiﬁcations and showed the
presence of an additional 3 Cff isolates from the so-called “culture
negative” samples. Due to time and cost constraints only 36 of the 70
anomalous results were investigated further. All 36 samples were re-
identiﬁed using the modiﬁed biotyping methods, with 4 samples also
being sent for AFLP analysis. When re-biotyped, 34 out of the 36
samples were then in agreement with PCR diagnosis. Only 2 samples
remained as the original biotype.
3.1. Data analysis/statistics
Overall for the Cf PCR versus biotyping the observed agreement
was 93.5% and the overall Kappa value was 0.9 with a 95% conﬁdence
interval from 0.877 to 0.922. The measure for the identiﬁcation of Cff
by PCR showed an observed agreement of 93.7% with biotyping, with
a kappa value of 0.87 and for the identiﬁcation of Cfv the PCR had an
observed agreement of 93.9% and a kappa value of 0.82. Based on the
1071 isolates tested the PCR sensitivity for the Cf and Cfv PCR assays
were 99.7% and 94.9% respectively. The speciﬁcity for the Cf and Cfv PCR
assays were 98.9% and 94.1% respectively. The McNemar test indicated
that the PCR test identiﬁes signiﬁcantly fewer samples (P = b0.0001,
chi squared = 29.785 with a 1° of freedom) as Cff than biotyping, and
more Cfv than would be expected by chance alone.
In the early stages of the project it was noted that the use of the
glycine and cysteine sensitivity assays using Mueller Hinton broths
was proving to be problematic and the main contributing factor
to mis-identiﬁcation. Consequently, these were replaced with blood
agar plates containing either glycine or cysteine which decreased
the discrepancies between biotyping and PCR signiﬁcantly. Therefore,
to measure the statistical quality of the data after changes were made
to the biotyping procedures a sub data set of 568 samples was taken.
The data were collated in chronological order and 527 samples from
the beginning of the study were removed. Data were analysed using
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ing into account re-biotyping and testing where there were discrepan-
cies. Overall for the Cf PCR versus biotyping the observed agreement
was 98.2% with a kappa value of 0.971. These ﬁgures change to an
agreement of 99.6% with a kappa value of 0.99 when re-biotyping and
retest data were considered. For the identiﬁcation of Cff by PCR the
observed agreement was 98.2% and the kappa value 0.96, changing to
99.6% and 0.99 after accommodating re-biotyping and retest data.
For identiﬁcation of Cfv by PCR the observed agreement was 98.9%
with a kappa value of 0.956, changing to 99.8% and 0.99 after accommo-
dating re-biotyping and retest data. The PCR sensitivity and speciﬁcity
for these data are shown in Table 4, with data after re-biotyping and
retest shown in brackets.4. Discussion
Bovine venereal campylobacteriosis (sometimes referred to as
Bovine Genital Campylobacteriosis) is a statutory disease. Consequently,
animals used for international trade purposes are obliged to complywith
testing for the presence of the causative agent, Campylobacter fetus
venerealis (Cfv). Based on biotyping methods, just under 300 conﬁrmed
cases of Cfv infection at AHVLA have been reported over the past 10
years in England andWales and the disease continues to be of signiﬁcant
economic importance. This is further highlighted by the increasing reli-
ance on natural service as opposed to artiﬁcial insemination. The poten-
tial for Cfv to increase in incidence as a consequence of this change is a
concern highlighting the importance of accurate and reliable screening
methods.
Accurate diagnosis is necessary to avoid the spread of the disease
and associated costs. Unfortunately, a closely related subspecies
Campylobacter fetus fetus (Cff), which is only sporadically associated
with bovine fertility issues, can interfere with the detection and
discrimination between the two bacteria. Therefore, over the years a
number of research groups have worked on trying to detect and dis-
criminate between Cff and Cfv, with the use of molecular based assays
for the genetic differentiation between Cfv and Cff remaining as a viable
option. However, at present the only approved OIE tests for subspecies
differentiation are selective culture/biotyping as well as AFLP (Anon,
2012).
From the small preliminary study it was conﬁrmed that current
biotyping methods used at AHVLA for C. fetus strains could be very
problematic (Table 2). Of the 15 strains used, 11 were obtained from
the AHVLA Weybridge archive, with the remaining 4 being NCTC con-
trol strains. When the PCRs were initially assessed there were discrep-
ancies in 4 out of the 11 isolates in that the PCR disagreed with the
biotyping analysis (data not shown). Only after further investigation
did it transpire that the PCR result was correct and that the four strains
had been incorrectly biotyped. This was an interesting early ﬁnding
and was an indication of the difﬁculties there had been historically in
differentiating Cfv and Cff through biotyping. It was at this stage that
the glycine and cysteine sensitivity methods were changed from using
Mueller Hinton broths to using blood agar plates. This change alone
made a signiﬁcant difference to the biotyping differential diagnosis
but highlighted the subjective nature of some of these tests.Table 4
Sensitivity and speciﬁcity of PCR assays.
N = 1071 Cf PCR (CampF4/R4) Cfv PCR (CampF7/R7)
Sensitivity (%) 100 (100) 97.6 (98.7)
Speciﬁcity (%) 98.4 (99.6) 99.6 (99.8)
Percentages shown in parenthesis indicate sensitivity and speciﬁcity when taking into
account resolution of discrepancies between PCR and biotyping.The preliminary study was designed to evaluate the potential use
of real time PCR assays to detect and discriminate between Cfv and
Cff. From Table 2, by analysing the raw data, taking into account the
Ct values and dissociation curves, 2 sets of in-house designed primers
namely; CampF4/R4 and CampF7/R7, were considered suitable for
further investigation. In the second phase of the study, a total of
1071 samples that had been biotyped using established OIE approved
methods were screened using these two optimised PCR primer sets.
Testing all 1071 boilates resulted in 70 samples (~6.5%) where biotyping
and PCR identiﬁcation differed (Table 3). The majority of these disagree-
ments occurred in the early stages of the study prior to the introduction
of blood agar plates containing either glycine or cysteine.
It must be recognised that the PCR assay is highly dependent on
the colony chosen to prepare the boilate. If a plate contains a mixed
culture then the PCR and biotyping analysis could differ if the same
colony is not chosen for both purposes. This may in part explain
some of the discrepancies between PCR and biotyping in this study.
Furthermore, in order to minimise any false positive results, the prep-
aration of these boilates is critical and it is recommended that the
ratio of 1 isolated colony to 500 μl of water is not exceeded. Conse-
quently, it was hypothesised in the 2 cases where biotyping and PCR
differed after reculture that the samples were either not a pure culture
or a consequence of PCR contamination.
Statistical analysis of a subset of data using samples tested after
changes to the biotyping identiﬁcationmethods, and taking into account
retest and re-biotyping information demonstrated a statistical improve-
ment (Table 4). After taking into account retest and reculture data, the
speciﬁcity and sensitivity of the C. fetus PCRwere 99.6% and 100% respec-
tively. For the identiﬁcation of Cfv by PCR, the speciﬁcity and sensitivity
were 99.8% and 98.7% respectively.
At present each boilate has to be tested by two separate PCRs
which is not ideal. Unfortunately, the PCR assays used in this study are
not suitable formultiplexing using SYBR®Green since the disassociated
curves for both products are very similar (data not shown). The
next stage is to adapt to a probe based PCR assay and see if it could
be multiplexed. Furthermore, with the increase in the occurrence of
C. fetus venerealis biovar “intermedius” it may be beneﬁcial if the PCR
could be adapted to detect and discriminate this from Cfv.
Finally, there is some additional data in the literature that suggests
that the effectiveness of the PCRs on closely related subspecies may
be dependent on the isolate's country of origin (Willoughby et al.,
2005). It would therefore also be useful to assess these primers on
isolates from countries other than the UK. A recent paper published
by Spence et al. (2011) suggested difﬁculties with the cross reaction
of a so-called “Cfv speciﬁc” PCR with C. hyointestinalis isolated in
New Zealand. In this study we assessed 16 C. hyointestinalis isolates
and there was no evidence of cross reactivity. To assess our primers
further we contacted Spence and requested a small set of DNA samples
that had cross reacted in their study to be sent unidentiﬁed. Again there
was no cross-reactivity with their C. hyointestinalis isolates and all
samples were correctly identiﬁed.
The results reported in this study would appear to emphasise the
difﬁculty in C. fetus discrimination by traditional biotyping methods
and conﬁrm the potential importance of the new PCR tests. Overall
we were able to show for the ﬁrst time that relatively simple molec-
ular tests (PCR) could be robustly utilised to detect and discriminate
between Cff and Cfv isolates. This study has allowed the AHVLA to
establish a molecular based discriminatory test to complement rou-
tine biotyping characterisation. The PCR is currently being used by
theAHVLAas an additional screenon all clinical bovine andovine samples
helping veterinary colleagues to implement the appropriate treatment.
Where any disagreements occur between the OIE approved biotyping
method and PCR, these samples are investigated further. Even with
the new and improved biotyping methods used by the AHVLA, the PCR
has raised one or two questions over possible mis-identiﬁcation and
continues to be a valuable supporting assay.
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Glossary
AFLP: Ampliﬁed Fragment Length Polymorphism
PFGE: Pulsed Field Gel Electrophoresis
PCR: Polymerase Chain Reaction
Cff: Campylobacter fetus fetus
Cfv: Campylobacter fetus venerealis
Cfvi: Campylobacter fetus venerealis biovar “intermedius”
AHVLA: Animal Health and Veterinary Laboratories Agency
